Overview 28 Day Repeat Dose in Cystic Fibrosis Patients Status: Completed Trial end date: 2010-12-29 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether the safety, tolerability and pharmacodynamics of SB656933 in patients that have cystic fibrosis Phase: Phase 2 Details Lead Sponsor: GlaxoSmithKline